Toronto, August 18, 2016 – Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring.
This announcement was covered in Yahoo Finance, The Canadian Business Journal, Global News Wire, and BioSpace.
Applied immediately after surgical wound closure, SCX-001 reduces the amount of scar tissue that develops during the body’s natural healing process. The 24-subject Phase I clinical trial will be conducted at ...
Canadian biotech company developing ground-breaking therapeutic designed to minimize dermal scarring (fibrosis)
TORONTO (February 16, 2016) — ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes.
This announcement was covered in TechVibes, BetaKit, Biotechnology Focus, PEHub, Finsmes, and StartupHere Toronto.
SCX-001 is the ...
MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring
VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis).
Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ...
ScarX Therapeutics, a MaRS Innovation start-up company from the Hospital for Sick Children, was featured in "Scars Defaced," a BioCentury emerging company profile by Michael J. Haas.
The profile is available to BioCentury subscribers on their website (paywall in place).
Here's a short excerpt:
ScarX Corp. has reformulated a generic analgesic that is marketed primarily in Europe into a topical cream that patients can self-administer
after surgery to prevent scarring. The company expects cosmetic and reconstructive surgeons to be early adopters of its topical nefopam, ...
MaRS Innovation (MI) seeks applicants for the Medical Sciences Proof-of-Principle (MSc PoP) program, which supports early-stage medical science technologies and allows their founding teams to conduct crucial proof-of-principle work.
Through the two-year MSc POP program, MI will distribute funding awards to qualified applicants within its membership on behalf of the Ministry of Research and Innovation (MRI). Funds are available in $25,000 or $75,000 grants.
“At MaRS Innovation, the PoP program functions as a kind of internal Dragons' Den,” says Dr. Raphael Hofstein, president ...
September 4, 2013
in BresoTec Inc., DLVR Therapeutics Inc, Encycle Therapeutics, Funding or Fundraising-Announcements, Government Partners, Kapplex, Licenseable Technologies, Member Institutions, News, Partnerships, Portfolio, ScarX Therapeutics, Start-Up Companies, TIAP Staff
Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog.
Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013.
The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, ...
May 2, 2013
in DLVR Therapeutics Inc, Encycle Therapeutics, Government Partners, Industry Partners, International Projects, MaRS Discovery District, Member Institutions, News, Partnerships, Portfolio, ScarX Therapeutics, Start-Up Companies, The Hospital for Sick Children (SickKids), University of Toronto
"More than 240 million surgeries are performed worldwide each year, yet there is no approved product on the market to prevent the dermal scarring that can frequently occur," writes Jennifer Boggs, managing editor of BioWorld Today in her cover story on ScarX Therapeutics.
The article, "ScarX Finds New Uses for Old Drug in Dermal Scarring," appeared in the New Co section and focuses on the MaRS Innovation-Hospital for Sick Children start-up company.
Here's an excerpt:
"ScarX Therapeutics, a 2012 Toronto-based start-up, is looking to ...
TORONTO, ON (Jan. 24, 2013) - ScarX Therapeutics, a start-up company commercializing a groundbreaking treatment to dramatically reduce post-operation scarring, is receiving a $250,000 investment from Ontario Centres of Excellence.
This story was covered in Yonge Street Media on January 30, 2013.
ScarX, a topical medication, emerged from Dr. Benjamin Alman's research. Alman, head of orthopedic surgery at the Hospital for Sick Children, is developing his invention in conjunction with MaRS Innovation.
Each year, doctors worldwide perform 240 million surgeries. Currently, no clinically-proven prescription ...
January 24, 2013
in Funding or Fundraising-Announcements, Government Partners, Media Coverage, Member Institutions, News, Partnerships, Portfolio, ScarX Therapeutics, Start-Up Companies, The Hospital for Sick Children (SickKids)
Happy New Year. Here's a snapshot of some spin-off stories you may have missed over the holiday break:
Flybits and Flybits Lite, the startup company's context-aware mobile technology that anyone can use, was mentioned in a Smithsonian.com article as one of six technologies changing the way the way humans live.
ApneaDx was featured in a company profile post on the MaRS Blog: "ApneaDx: First we take Ontario, then we take the world."
ScarX Therapeutics launched its website.
OtoSim Inc. co-founder Dr. Vito ...
ScarX Therapeutics, a spin-off company created by MaRS Innovation and The Hospital for Sick Children (SickKids), was profiled by Business Without Borders on September 25, 2012.
Sean Fine's article examines the strategic funding partnership MI pursued with NovoTek Therapeutics Inc. (NovoTek) in China to develop the anti-scarring cream, which was discovered by researchers at SickKids.
A multibillion-dollar market may await ScarX, a Toronto biomedical start-up, but first it had to figure out how to finance the development of its unique cream that reduces scarring ...